Phase 2a Randomized Placebo-Controlled Double-Blind Multicenter Trial of VIB4920 for Active Lupus Nephritis
Primary Objective
To evaluate the efficacy of VIB4920 antoagonism of CD40L in achieving a complete renal response in active lupus nephritis
Description
A double-blind, placebo-controlled trial of investigational agent combined with MMF.
Details
Age
Adult
Eligibility
SLE; age 18 or olderUPCR ≥ 1.0 based on a 24-hour urine collection at Visit -1.
Renal biopsy within 24 weeks prior to Visit -1 of ISN/RPS LN [5, 6] with both of the following:
a.
Class III, Class IV, or Class V in combination with Class III or IV, and
b.
Modified NIH Activity Index ≥ 1.
Locations
Renal Research Center
University of Colorado Hospital
Principal Investigator
Amber Podoll
Study ID
Protocol Number: 22-0596
More information available at ClinicalTrials.gov: NCT05201469
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers